CN1277554A - 葡糖胺聚糖在生产用于治疗与糖尿病有关的眼疾病的药物制剂中的用途 - Google Patents

葡糖胺聚糖在生产用于治疗与糖尿病有关的眼疾病的药物制剂中的用途 Download PDF

Info

Publication number: CN1277554A
Authority: CN; China
Prior art keywords: glucosaminoglycan; purposes; treatment; diabetes; administration
Prior art date: 1997-10-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN98810527A

Other languages

English (en)

Chinese (zh)

Inventor

F·范德沃德

D·赫尔

V·劳克斯

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott GmbH and Co KG

Original Assignee

Knoll GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-24

Filing date

1998-10-22

Publication date

2000-12-20

1998-10-22 Application filed by Knoll GmbH filed Critical Knoll GmbH

2000-12-20 Publication of CN1277554A publication Critical patent/CN1277554A/zh

Status Pending legal-status Critical Current

Links

206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 22
239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 11
201000010099 disease Diseases 0.000 title abstract description 10
229920002683 Glycosaminoglycan Polymers 0.000 title abstract description 3
238000011282 treatment Methods 0.000 claims description 36
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 35
229920000669 heparin Polymers 0.000 claims description 33
239000003814 drug Substances 0.000 claims description 21
229960002897 heparin Drugs 0.000 claims description 14
210000004369 blood Anatomy 0.000 claims description 13
239000008280 blood Substances 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 13
239000000463 material Substances 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
230000037396 body weight Effects 0.000 claims description 10
229920000045 Dermatan sulfate Polymers 0.000 claims description 9
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 9
229940051593 dermatan sulfate Drugs 0.000 claims description 9
239000003055 low molecular weight heparin Substances 0.000 claims description 9
229940127215 low-molecular weight heparin Drugs 0.000 claims description 9
239000000203 mixture Substances 0.000 claims description 9
241001597008 Nomeidae Species 0.000 claims description 8
-1 sulphuric acid xylan Chemical class 0.000 claims description 8
229920002971 Heparan sulfate Polymers 0.000 claims description 6
206010020772 Hypertension Diseases 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 3
239000001117 sulphuric acid Substances 0.000 claims description 3
235000011149 sulphuric acid Nutrition 0.000 claims description 3
239000005541 ACE inhibitor Substances 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
229960000633 dextran sulfate Drugs 0.000 claims description 2
229960003401 ramipril Drugs 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
229920001221 xylan Polymers 0.000 claims description 2
229940077927 altace Drugs 0.000 claims 1
241001465754 Metazoa Species 0.000 description 20
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 20
229960005496 reviparin Drugs 0.000 description 20
238000000034 method Methods 0.000 description 18
208000017442 Retinal disease Diseases 0.000 description 14
206010038923 Retinopathy Diseases 0.000 description 14
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
102000004877 Insulin Human genes 0.000 description 10
108090001061 Insulin Proteins 0.000 description 10
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 10
239000008103 glucose Substances 0.000 description 10
229940125396 insulin Drugs 0.000 description 10
238000011160 research Methods 0.000 description 10
ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 9
229960001052 streptozocin Drugs 0.000 description 9
206010012689 Diabetic retinopathy Diseases 0.000 description 8
239000011248 coating agent Substances 0.000 description 8
238000000576 coating method Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000007920 subcutaneous administration Methods 0.000 description 8
238000012360 testing method Methods 0.000 description 8
241000700159 Rattus Species 0.000 description 7
239000000460 chlorine Substances 0.000 description 6
238000011835 investigation Methods 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
230000006872 improvement Effects 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
238000012545 processing Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
108090000935 Antithrombin III Proteins 0.000 description 4
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000015271 coagulation Effects 0.000 description 4
238000005345 coagulation Methods 0.000 description 4
230000006866 deterioration Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
230000008728 vascular permeability Effects 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
102100022977 Antithrombin-III Human genes 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000001554 Hemoglobins Human genes 0.000 description 3
108010054147 Hemoglobins Proteins 0.000 description 3
206010027525 Microalbuminuria Diseases 0.000 description 3
208000009857 Microaneurysm Diseases 0.000 description 3
206010038934 Retinopathy proliferative Diseases 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
229940109239 creatinine Drugs 0.000 description 3
238000011161 development Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000002651 drug therapy Methods 0.000 description 3
210000000416 exudates and transudate Anatomy 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
150000004804 polysaccharides Chemical class 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000002435 venom Substances 0.000 description 3
210000001048 venom Anatomy 0.000 description 3
231100000611 venom Toxicity 0.000 description 3
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 2
102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 2
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010025421 Macule Diseases 0.000 description 2
208000037111 Retinal Hemorrhage Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000003513 alkali Substances 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
201000007917 background diabetic retinopathy Diseases 0.000 description 2
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000009530 blood pressure measurement Methods 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
150000002016 disaccharides Chemical group 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000037406 food intake Effects 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
150000002337 glycosamines Chemical class 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
239000004922 lacquer Substances 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000007774 longterm Effects 0.000 description 2
206010025482 malaise Diseases 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 2
229960000381 omeprazole Drugs 0.000 description 2
230000000649 photocoagulation Effects 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
201000007914 proliferative diabetic retinopathy Diseases 0.000 description 2
230000036454 renin-angiotensin system Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
206010001580 Albuminuria Diseases 0.000 description 1
229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
229940123413 Angiotensin II antagonist Drugs 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000271517 Bothrops jararaca Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
102000002045 Endothelin Human genes 0.000 description 1
108050009340 Endothelin Proteins 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
208000003790 Foot Ulcer Diseases 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
229920001503 Glucan Polymers 0.000 description 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
102000005237 Isophane Insulin Human genes 0.000 description 1
108010081368 Isophane Insulin Proteins 0.000 description 1
229920000288 Keratan sulfate Polymers 0.000 description 1
206010064000 Lichenoid keratosis Diseases 0.000 description 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
125000003047 N-acetyl group Chemical group 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
208000007542 Paresis Diseases 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
206010040943 Skin Ulcer Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
241000282485 Vulpes vulpes Species 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001858 anti-Xa Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
230000002402 anti-lipaemic effect Effects 0.000 description 1
229940125713 antianxiety drug Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
229940067131 aspirin 100 mg Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
JCSJTDYCNQHPRJ-MMDFAQQLSA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-beta-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)OC2)O)OC1 JCSJTDYCNQHPRJ-MMDFAQQLSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000002371 cardiac agent Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
230000001112 coagulating effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
229960002086 dextran Drugs 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
201000005577 familial hyperlipidemia Diseases 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
239000010408 film Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
229960003765 fluvastatin Drugs 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000004083 gastrointestinal agent Substances 0.000 description 1
229940127227 gastrointestinal drug Drugs 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
206010019465 hemiparesis Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
229960002003 hydrochlorothiazide Drugs 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
229960001848 lamotrigine Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
206010024378 leukocytosis Diseases 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
201000011486 lichen planus Diseases 0.000 description 1
238000007449 liver function test Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
229960004391 lorazepam Drugs 0.000 description 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
229960004844 lovastatin Drugs 0.000 description 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
229960002237 metoprolol Drugs 0.000 description 1
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
229960004027 molsidomine Drugs 0.000 description 1
229960003938 moxonidine Drugs 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229960000227 nisoldipine Drugs 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
231100001035 ocular change Toxicity 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000007170 pathology Effects 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
206010034754 petechiae Diseases 0.000 description 1
238000000053 physical method Methods 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
239000002461 renin inhibitor Substances 0.000 description 1
229940086526 renin-inhibitors Drugs 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000004092 self-diagnosis Methods 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
238000009936 smoking Methods 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
229940093252 sorbitrate Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000003637 steroidlike Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000001180 sulfating effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000007885 tablet disintegrant Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
229960005461 torasemide Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
210000003462 vein Anatomy 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)

CN98810527A 1997-10-24 1998-10-22 葡糖胺聚糖在生产用于治疗与糖尿病有关的眼疾病的药物制剂中的用途 Pending CN1277554A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19747195A DE19747195A1 (de)	1997-10-24	1997-10-24	Verwendung von Glykosaminoglykanen zur Herstellung von pharmazeutischen Zubereitungen zur Behandlung von mit Diabetes assoziierten Augenkrankheiten
DE19747195.1		1997-10-24

Publications (1)

Publication Number	Publication Date
CN1277554A true CN1277554A (zh)	2000-12-20

Family

ID=7846613

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN98810527A Pending CN1277554A (zh)	1997-10-24	1998-10-22	葡糖胺聚糖在生产用于治疗与糖尿病有关的眼疾病的药物制剂中的用途

Country Status (13)

Country	Link
EP (1)	EP1047434A2 (de)
JP (1)	JP2001520987A (de)
KR (1)	KR20010024550A (de)
CN (1)	CN1277554A (de)
AU (1)	AU749673B2 (de)
BR (1)	BR9813098A (de)
CA (1)	CA2306379A1 (de)
DE (1)	DE19747195A1 (de)
HU (1)	HUP0004647A3 (de)
IL (1)	IL135171A0 (de)
NO (1)	NO20001895D0 (de)
WO (1)	WO1999021538A2 (de)
ZA (1)	ZA989665B (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101584704B (zh) *	2008-05-23	2010-12-15	鲁南制药集团股份有限公司	肝素、低分子肝素可药用盐或其衍生物的医药用途
CN107137421A (zh) *	2017-05-25	2017-09-08	青岛市中心医院	硫酸葡聚糖在制备抑制角膜血管新生药物中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI991503A1 (it) *	1999-07-08	2001-01-08	Bidifarm S R L	Uso di metaboliti oligosaccaridici di proteoglicani come maker in fluidi biologici di diagnosi del biabete e delle complicanze patologiche c
JPWO2011122321A1 (ja) *	2010-03-29	2013-07-08	国立大学法人名古屋大学	ヘパリン結合性蛋白に対する生理活性阻害剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2597484B1 (fr) *	1986-04-17	1988-12-23	Sanofi Sa	Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques.
JPH03500168A (ja) *	1988-06-27	1991-01-17	ライナー　ローラント	医薬の製造の為のグリコースアミノグリカンの使用
US5135920A (en) *	1988-11-16	1992-08-04	Takeda Chemical Industries, Ltd.	Angiostatic agents
PT93847A (pt) *	1989-04-24	1990-11-20	Harvard College	Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
WO1995005182A1 (en) *	1993-08-13	1995-02-23	Glycomed Incorporated	Bridged oligosaccharides and sulfated derivatives thereof
AU700451B2 (en) *	1993-10-07	1999-01-07	Glycomed Incorporated	Highly sulfated maltooligosaccharides with heparin-like properties
US5643892A (en) *	1995-06-07	1997-07-01	Baker Norton Pharmaceuticals, Inc.	Method of treating chronic progressive vascular diseases
WO1999004801A1 (en) *	1997-07-28	1999-02-04	Rijks Universiteit Leiden	Use of sulfated glycosaminoglycans for treating of retinopathy

1997
- 1997-10-24 DE DE19747195A patent/DE19747195A1/de not_active Withdrawn
1998
- 1998-10-22 CA CA002306379A patent/CA2306379A1/en not_active Abandoned
- 1998-10-22 BR BR9813098-6A patent/BR9813098A/pt not_active IP Right Cessation
- 1998-10-22 AU AU13355/99A patent/AU749673B2/en not_active Ceased
- 1998-10-22 KR KR1020007004363A patent/KR20010024550A/ko not_active Application Discontinuation
- 1998-10-22 EP EP98956862A patent/EP1047434A2/de not_active Withdrawn
- 1998-10-22 JP JP2000517697A patent/JP2001520987A/ja active Pending
- 1998-10-22 HU HU0004647A patent/HUP0004647A3/hu unknown
- 1998-10-22 CN CN98810527A patent/CN1277554A/zh active Pending
- 1998-10-22 IL IL13517198A patent/IL135171A0/xx unknown
- 1998-10-22 WO PCT/EP1998/006703 patent/WO1999021538A2/de not_active Application Discontinuation
- 1998-10-23 ZA ZA9809665A patent/ZA989665B/xx unknown
2000
- 2000-04-12 NO NO20001895A patent/NO20001895D0/no not_active Application Discontinuation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101584704B (zh) *	2008-05-23	2010-12-15	鲁南制药集团股份有限公司	肝素、低分子肝素可药用盐或其衍生物的医药用途
CN107137421A (zh) *	2017-05-25	2017-09-08	青岛市中心医院	硫酸葡聚糖在制备抑制角膜血管新生药物中的应用

Also Published As

Publication number	Publication date
DE19747195A1 (de)	1999-04-29
AU749673B2 (en)	2002-07-04
HUP0004647A3 (en)	2002-01-28
JP2001520987A (ja)	2001-11-06
WO1999021538A2 (de)	1999-05-06
EP1047434A2 (de)	2000-11-02
NO20001895L (no)	2000-04-12
WO1999021538A3 (de)	1999-08-05
NO20001895D0 (no)	2000-04-12
BR9813098A (pt)	2000-08-15
CA2306379A1 (en)	1999-05-06
IL135171A0 (en)	2001-05-20
ZA989665B (en)	2000-04-25
HUP0004647A2 (hu)	2001-05-28
AU1335599A (en)	1999-05-17
KR20010024550A (ko)	2001-03-26

Legal Events

Date	Code	Title	Description
2000-12-20	C06	Publication
2000-12-20	PB01	Publication
2000-12-27	C10	Entry into substantive examination
2000-12-27	SE01	Entry into force of request for substantive examination
2004-07-14	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2004-07-14	WD01	Invention patent application deemed withdrawn after publication
2007-06-01	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1033428 Country of ref document: HK

Publication	Publication Date	Title
RU2519660C2 (ru)	2014-06-20	Режим дозировки селективного агониста рецептора s1p1
CN1268339C (zh)	2006-08-09	Rosuvastatin(zd－4522)在制备治疗杂合家族性高胆固醇血症的药物中的应用
CN110420315A (zh)	2019-11-08	枸杞糖肽在制备治疗三高药物中的应用
CN1373753A (zh)	2002-10-09	氨氮地平和阿托伐他汀的公共盐
RU2201272C2 (ru)	2003-03-27	Применение ингибиторов желудочно-кишечной липазы
CA2678319A1 (en)	2008-08-21	Use of ranolazine for the treatment of coronary microvascular diseases
Carrillo et al.	2015	Double filtration plasmapheresis in the treatment of pancreatitis due to severe hypertriglyceridemia
CN105228453A (zh)	2016-01-06	用于治疗与炎症相关的疾病的去乙基羟氯喹
CN1717234A (zh)	2006-01-04	用于治疗眼紊乱和疾病的超氧化物岐化酶模拟物
CN101057859A (zh)	2007-10-24	一种解聚海参糖胺聚糖组合物及其制备方法和用途
CN103328983A (zh)	2013-09-25	决奈达隆在制备用于控制肝损伤风险的药物中的用途
CN101032512A (zh)	2007-09-12	一种用于扩充血容量的药物组合物及其制备方法
CN1277554A (zh)	2000-12-20	葡糖胺聚糖在生产用于治疗与糖尿病有关的眼疾病的药物制剂中的用途
CN1679924A (zh)	2005-10-12	复方胰岛素能量合剂制剂及其应用
JP2001089382A (ja)	2001-04-03	早期血管再生及び低分子量ヘパリン投与による不安定冠動脈疾患の治療方法
CN1323675C (zh)	2007-07-04	菊苣水提取物的新用途
US20220202857A1 (en)	2022-06-30	Systems and methods for reducing low attenuation plaque and/or plaque burden in patients
CN110520120A (zh)	2019-11-29	药物活性成分及其用途，特别是用于预防和治疗人和动物中的代谢紊乱
CN1878557A (zh)	2006-12-13	用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物
EA018442B1 (ru)	2013-08-30	Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом
CN1263093A (zh)	2000-08-16	甲磺酸氨氯地平及其制法和应用
Septian et al.	2024	47. Non-atherosclerotic Myocardial Infarction (MI) as The Consequence of Hypertensive Emergencies (HE): what is the underlying possible mechanism?
Sheeba et al.	2019	Renal Tubular Acidosis (RTA) due to Sjögren’s Syndrome Presenting as Hypokalemic Quadriparesis
US20230355561A1 (en)	2023-11-09	N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated tgf-beta activation and fibrosis
JP2875541B2 (ja)	1999-03-31	血行再建術後の再閉塞防止剤

CN1277554A - 葡糖胺聚糖在生产用于治疗与糖尿病有关的眼疾病的药物制剂中的用途 - Google Patents

Info

Links

Images

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=7846613

Family Applications (1)

Country Status (13)

Cited By (2)

Families Citing this family (2)

Family Cites Families (8)

Cited By (2)

Also Published As

Similar Documents

Legal Events